Related Experiment Videos
Current medical treatment of pancreatic neuroendocrine tumors
Suayib Yalcin1, Basak Oyan, Yusuf Bayraktar
1Hacettepe University, Institute of Oncology, Department of Medical Oncology, Ankara, Turkey. syalcin@hacettepe.edu.tr
Abstract:
Pancreatic neuroendocrine tumors (NETs) consist of a wide group of neoplasms, with different biological behaviors in terms of aggressiveness and hormone production. In the last two decades, significant progress has been observed in our understanding of their biology, diagnosis and treatment. Surgery remains to be the only curative approach, but unfortunately the diagnosis is often delayed due to the slow growth of these tumors and the difficulty in identifying the symptoms related to the tumor-released hormones. In addition to surgery, other approaches to control the disease are biological therapy consisting of somatostatin analogs and interferon (IFN), systemic chemotherapy, radioligand therapy and local therapy with chemoembolization. Several newer cytotoxic agents, including irinotecan, gemcitabine, taxanes, oxaliplatin, capecitabine and PS-341 have been studied in metastatic patients. Considering the high vascularity of these tumors, antiangiogenic agents like endostatin and thalidomide have also been evaluated in advanced NETs. Although these agents seem to have potential activity in NETs and may increase progression free survival, none of these currently available medical therapeutic options are curative. While more efficient novel strategies are to be developed, the rationale use of the current therapeutic options may improve quality of life, control the symptoms related to the hypersecretion of hormones and/or peptides, control tumor proliferation and prolong survival in patients suffering from NETs.
Insights
Pancreatic neuroendocrine tumors (NETs) are diverse neoplasms. While surgery offers a cure, current medical therapies manage symptoms and prolong survival but are not curative.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Pancreatic neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms with variable aggressiveness and hormone production.
- Despite recent advances, diagnosis is often delayed due to slow growth and subtle hormonal symptoms.
- Surgery is the only curative treatment, but recurrence is common.
Purpose of the Study:
- To review the current understanding of pancreatic NET biology, diagnosis, and treatment.
- To evaluate the efficacy of existing and emerging therapies for advanced and metastatic NETs.
- To highlight the need for novel, curative strategies.
Main Methods:
- Review of current literature on pancreatic NETs.
- Analysis of therapeutic approaches including surgery, somatostatin analogs, interferon, chemotherapy, radioligand therapy, chemoembolization, and antiangiogenic agents.
- Evaluation of newer cytotoxic and antiangiogenic agents in metastatic NETs.
Main Results:
- Surgery remains the sole curative option for pancreatic NETs.
- Various medical therapies (somatostatin analogs, chemotherapy, antiangiogenic agents) can control disease progression, manage symptoms, and improve survival.
- No current non-surgical therapy is curative, though some agents show potential for increased progression-free survival.
Conclusions:
- Current medical therapies for pancreatic NETs can improve quality of life, control hormone hypersecretion, and prolong survival.
- Novel and more effective therapeutic strategies are needed for a curative approach.
- Rational use of existing treatments is crucial for managing advanced pancreatic NETs.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists